Investment management company Vulcan Value Partners recently released its fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. All the strategies of Vulcan Value Partners delivered positive results in the year. The Large Cap Composite (Net) returned -1.5% in Q4 and 7.9% YTD, the Small Cap Composite (Net) gained 3.2% in Q4 and 9.5% YTD, The Focus Composite (Net) retuned 0.1% in Q4 and 7.1% YTD, Focus Plus Composite (Net) returned 0.1% in Q4 and 6.2% YTD and the All-Cap Composite ...

Training specifically is a problem, with sites frequently being asked to conduct training multiple times, even though it remains valid from a previous study. This adds to timelines as it delays enrolment while site staff repeat tasks. Shetty agrees that sites are often asked to conduct redundant training, which could also include training they do not require as part of their roles in the trial.Areas of delay include start-up and training, which Bechtel says can be a huge area of inefficiency for sites.This ...

FORT MYERS, Fla., Jan. 15, 2026 (GLOBE NEWSWIRE) -- American Oncology Research, LLC (AOR), and Meaningful Insights Biotech Analytics, LLC (MiBA), today announced a strategic partnership designed to align operational infrastructure with advanced data intelligence in community oncology. By integrating AOR’s site management capabilities with MiBA’s AI-enhanced data ecosystem, the alliance creates a unified framework that closes gaps between study design, site feasibility and patient access. The collaboration ...

Trialbee has received a majority investment from Varsity Healthcare Partners (VHP) to accelerate its technology-driven patient recruitment solutions for clinical trials. The investment aims to expand Trialbee’s Honey Platform and enhance enterprise-level recruitment services for biopharma sponsors. It will enable further international expansion, development of its Omnichannel partner ecosystem, and continued improvement of its technology platforms. Over the past year, Trialbee has broadened its platfor ...

Core Viewpoint - ICON Public Limited Company (NASDAQ:ICLR) is considered a cheap healthcare stock with potential for investment as it heads into 2026, maintaining a 'Market Perform' rating and a price target of $175 by BMO Capital [1][4]. Group 1: Company Performance and Outlook - The company is experiencing elevated cancellation rates, which are expected to persist in the upcoming quarters, although it is believed to have passed through its worst period [4]. - ICON is focusing on increasing investments in automation and agentic AI, which may enhance its operational efficiency [2]. - The company has a one-year median price target of $213.50, indicating an upside potential of nearly 15% from its current levels [5]. Group 2: Analyst Insights - BMO Capital initiated coverage on ICON on November 13, maintaining a 'Market Perform' rating and a price target of $175, reflecting a cautious but optimistic outlook [4]. - Analysts covering the stock generally have a 'Buy' or equivalent rating, suggesting a positive sentiment towards ICON's future performance [5].

RESEARCH TRIANGLE PARK, N.C.--([BUSINESS WIRE](https://www.businesswire.com))--GXP- Storage®, a life sciences leader in compliant, visible and scalable material management, announced today the appointment of Chris Otto as an Independent Board Member, effective November 12, 2025. With over three decades of global clinical research and development experience, Otto brings deep operational expertise from his career at Eli Lilly and Company, where he most recently served as Global Leader and Associate Vice Presi ...

Core Insights - ICON plc, a leading clinical research organization, released results from a survey highlighting challenges faced by clinical trial sites during study startup [1] - The survey emphasizes the necessity for a site-centric and collaborative approach to address bottlenecks and improve trial activation timelines [1] Survey Details - The survey was conducted in June 2025 and included responses from over 100 principal investigators and senior clinical trial site personnel [1] - Findings indicate significant operational challenges that require strategic solutions to enhance efficiency in clinical trials [1]

Core Insights - ICON plc, a leading clinical research organization, released results from an industry survey highlighting challenges faced by clinical trial sites during study startup [1] - The survey emphasizes the necessity for a site-centric and collaborative approach to address bottlenecks and improve trial activation timelines [1] Survey Details - The survey was conducted in June 2025 and included responses from over 100 principal investigators and senior personnel at clinical trial sites [1] - Findings indicate that there are significant obstacles in the study startup process that need to be addressed to enhance efficiency [1]

Core Insights - Silo Pharma, Inc. has selected Allucent to assist in the final preparations for its investigational new drug application (IND) for the Phase 1 clinical trial of its intranasal prophylactic SPC-15 aimed at treating PTSD, with plans to submit the IND in 2026 [1][2] - The partnership with Allucent is viewed as a significant advancement in bringing the PTSD therapeutic to clinical trials, leveraging Allucent's expertise to ensure a robust IND submission [2] - Silo Pharma's therapeutic focus includes addressing underserved conditions such as stress-induced psychiatric disorders, chronic pain, and CNS diseases, with a portfolio that includes SPC-15 for PTSD and other programs targeting fibromyalgia and Alzheimer's disease [3] Company Overview - Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, focusing on innovative programs for various medical conditions [3] - The company collaborates with leading universities and laboratories to conduct its research [3] Allucent Overview - Allucent is a global full-service clinical research organization with over 30 years of experience, providing comprehensive drug development solutions across various therapeutic areas [4] - The organization aims to assist biopharma and government clients in overcoming challenges in bringing new therapies to market [4]

Core Insights - ClearBridge Investments reported that mid-cap stocks experienced growth in Q3 2025, driven by a favorable monetary policy environment and stabilizing earnings [1] - The Federal Reserve's rate cuts positively impacted small and mid-cap stocks, with value stocks outperforming growth stocks [1] - The ClearBridge Mid Cap Strategy outperformed the Russell Midcap Index, primarily due to stock selection in the consumer staples and healthcare sectors [1] Company-Specific Insights - ICON Public Limited Company (NASDAQ:ICLR) is highlighted as a key stock in the ClearBridge Mid Cap Strategy, despite a one-month return of -13.01% and a 52-week loss of 19.85% [2] - As of November 12, 2025, ICON's stock closed at $163.42, with a market capitalization of $12.479 billion [2] - The company reported Q3 2025 revenue of $2.043 billion, reflecting a year-on-year increase of 0.6% [4] - ICON's performance was supported by strong business wins and an expanding backlog, indicating potential improvement in the clinical research services sector [3]